AngioDynamics (NASDAQ:ANGO) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of AngioDynamics (NASDAQ:ANGO) from a sell rating to a hold rating in a report issued on Tuesday morning, BidAskClub reports.

A number of other equities analysts have also weighed in on ANGO. Zacks Investment Research raised AngioDynamics from a sell rating to a hold rating and set a $20.00 target price on the stock in a research report on Tuesday, June 4th. TheStreet lowered AngioDynamics from a b rating to a c+ rating in a research report on Thursday, April 18th. Finally, ValuEngine lowered AngioDynamics from a buy rating to a hold rating in a research report on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating, AngioDynamics currently has an average rating of Hold and a consensus price target of $21.50.

Shares of NASDAQ:ANGO opened at $19.58 on Tuesday. The company has a current ratio of 2.68, a quick ratio of 1.70 and a debt-to-equity ratio of 0.23. AngioDynamics has a twelve month low of $18.11 and a twelve month high of $25.48. The company has a market cap of $723.10 million, a PE ratio of 25.23 and a beta of 0.71.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, April 2nd. The medical instruments supplier reported $0.19 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.03). AngioDynamics had a return on equity of 5.41% and a net margin of 1.30%. The firm had revenue of $86.34 million for the quarter, compared to analyst estimates of $88.30 million. During the same period in the previous year, the company earned $0.23 earnings per share. AngioDynamics’s revenue for the quarter was up 3.0% compared to the same quarter last year. Equities analysts predict that AngioDynamics will post 0.83 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the stock. Thrivent Financial for Lutherans grew its holdings in AngioDynamics by 2.2% during the fourth quarter. Thrivent Financial for Lutherans now owns 26,360 shares of the medical instruments supplier’s stock worth $531,000 after buying an additional 579 shares in the last quarter. Advisor Group Inc. grew its holdings in AngioDynamics by 21.4% during the fourth quarter. Advisor Group Inc. now owns 3,405 shares of the medical instruments supplier’s stock worth $68,000 after buying an additional 601 shares in the last quarter. Texas Permanent School Fund grew its holdings in AngioDynamics by 3.8% during the first quarter. Texas Permanent School Fund now owns 25,215 shares of the medical instruments supplier’s stock worth $576,000 after buying an additional 923 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in AngioDynamics by 28.6% during the fourth quarter. PNC Financial Services Group Inc. now owns 5,315 shares of the medical instruments supplier’s stock worth $107,000 after buying an additional 1,181 shares in the last quarter. Finally, Swiss National Bank grew its holdings in AngioDynamics by 2.1% during the first quarter. Swiss National Bank now owns 67,700 shares of the medical instruments supplier’s stock worth $1,548,000 after buying an additional 1,400 shares in the last quarter. Institutional investors and hedge funds own 98.46% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Read More: How to find the components of the quick ratio

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.